Janus kinase (JAK) inhibitors, biologics and more—Dr. Laura Coates discussed the management of PsA, providing insights into the current research and when clinicians may want to consider prescribing specific medications.
B Original
Experts discussed how aspects of the immune system other than B cells play a role in lupus, including mitochondria in red blood cells, proteins present in urine and more.
Past ACR President Named a PANLAR Master
This spring, PANLAR designated Mary K. Crow, MD, a Master of Rheumatology. She was honored for her career in research and work extending research opportunities to investigators in Latin America.
Rheumatologists Across Borders
The EULAR/ACR/APLAR Research Exchange Program is an opportunity to learn and exchange ideas within the rheumatology community internationally. Here the program’s most recent participants share their experiences & excitement.
Through Thick & Thin: Updates in Scleroderma
Pulmonary hypertension and Raynaud’s phenomenon are just some of the symptoms patients with systemic sclerosis (SSc) may experience. Here are insights into the diagnosis and management of SSc.
Strong Argument: Recent Developments in Myositis Diagnosis & Care
Lisa Christopher-Stine, MD, MPH, discussed the latest findings on myositis and its subtypes, including insights into antibodies linked to cancer and treatments for these patients.
The Great Imitator: Updates on Sarcoidosis
Michelle Sharp, MD, MHS, shared insights into the complexities of sarcoidosis, describing how she evaluates, diagnoses and treats patients.
Skin Matters: The Intersection of Dermatology & Rheumatology
Jun Kang, MD, addressed the intersection of dermatology and rheumatology, describing the nuance necessary to accurately evaluate skin manifestations and differentiate multiple conditions.
Under Pressure: Understanding Dysautonomia & POTS
Brit Adler, MD, provided a detailed analysis into the symptoms and management of patients with postural orthostatic tachycardia syndrome.
15,000 Patient-Years: Safety Data for Upadacitinib Treatment Across Multiple Rheumatic Conditions
Burmester et al. characterized the long-term safety profile of upadacitinib treatment across multiple rheumatic diseases.
- 1
- 2
- 3
- …
- 13
- Next Page »